Sign in →

Test Code LABSAGG Saccharomyces cerevisiae Antibody, IgG, Serum

Additional Codes

Test Name in EPIC EPIC Test Code Mnemonic Mayo Test ID


Reporting Name

Saccharomyces cerevisiae Ab, IgG, S

Useful For

Helping clinicians distinguish between ulcerative colitis and Crohn's disease in patients suspected of having inflammatory bowel disease

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type


Specimen Required


Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.50 mL

Specimen Minimum Volume

0.4 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Reject Due To


Mild OK; Gross reject


Mild OK; Gross reject


Mild OK; Gross OK



Reference Values

Negative: ≤20.0 U

Equivocal: 20.1-24.9 U

Weakly positive: 25.0-34.9 U

Positive: ≥35.0 U

Reference values apply to all ages.

Day(s) and Time(s) Performed

Monday through Friday; 5 p.m.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
GASCA Saccharomyces cerevisiae Ab, IgG, S 47321-5


Result ID Test Result Name Result LOINC Value
GASCA Saccharomyces cerevisiae Ab, IgG, S 47321-5

Analytic Time

Same day/1 day


IBDP / Inflammatory Bowel Disease Serology Panel, Serum is useful as an adjunct in the diagnosis of ulcerative colitis (UC) and Crohn's disease (CD), but should not be relied upon exclusively to establish the diagnosis or to distinguish between these 2 diseases. Some patients with CD have detectable neutrophil-specific antibodies (NSA), and some patients with UC have elevated levels of IgA and/or IgG anti-Saccharomyces cerevisiae antibodies (ASCA).


Measurement of ASCA and NSA are not useful to determine the extent of disease in patients with inflammatory bowel disease or to determine the response to disease-specific therapy including surgical resection of diseased intestine.

Method Description

IgG anti-Saccharomyces cerevisiae antibodies (ASCA) are measured by commercial, microtiter enzyme immunoassays (INOVA Diagnostics, San Diego, CA). This assay uses polystyrene microtiter plates coated with partially purified Saccharomyces cerevisiae antigens to capture antibodies from patient's sera and horseradish peroxidase-conjugated anti-IgG antibodies to detect IgG ASCA. Results of the test for IgG ASCA are reported in arbitrary units.(Package insert: QUANTA LITE ASCA [Saccharomyces cerevisiae] IgG ELISA 708865)


In IBDP / Inflammatory Bowel Disease Serology Panel, Serum, anti-Saccharomyces cerevisiae antibodies (ASCA) and neutrophil-specific antibodies (NSA) are measured. The finding of NSA with normal levels of IgA and IgG ASCA is consistent with the diagnosis of ulcerative colitis (UC); the finding of negative NSA with elevated IgA and IgG ASCA is consistent with Crohn's disease (CD).


NSA are detectable in approximately 50% of patients with UC.


Elevated levels of either IgA or IgG ASCA occur in approximately 55% of patients with CD. Elevated levels of both IgA and IgG ASCA occur in approximately 40% of patients with CD.


Employed together, the tests for NSA and ASCA have the following positive predictive values (PPV) for UC and CD, respectively:(2)

-NSA-positive with normal levels of IgA and IgG ASCA, PPV of 91%

-NSA-negative with elevated levels of IgA and IgG ASCA, PPV of 90%

Specimen Retention Time

7 days

Clinical Information

Inflammatory bowel disease (IBD) refers to 2 diseases, ulcerative colitis (UC) and Crohn's disease (CD), which produce inflammation of the large or small intestines.(1) The diagnoses of both diseases are based on clinical features, radiographic findings, colonoscopy, mucosal biopsy histology, and, in some cases, operative findings and resected bowel pathology and histology.


Patients with IBD have also been shown to have antibodies in serum that help distinguish between CD and UC.(2) Patients with UC often have measurable neutrophil-specific antibodies (NSA) that react with as yet uncharacterized target antigens in human neutrophils; whereas patients with CD often have measurable antibodies of the IgA and/or IgG isotypes that react with cell wall mannan of Saccharomyces cerevisiae strain Su 1.

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.


If not ordering electronically, complete, print, and send a Gastroenterology and Hepatology Test Request Form (T728) with the specimen (